PRKAR2B and prostate cancer: However, knock-down of PRKAR2B expression through siRNA in LNCaP did not significantly alter cell invasion capability (Supplementary Figure S1C), indicating that PRKAR2B plays more oncogenic roles, such as cell invasion, in castration-resistant prostate cancer cell compared to that in castration-sensitive prostate cancer cell.